Benefits (Research Focus) NNMT inhibition studied as a selective small-molecule inhibitor of nicotinamide N-methyltransferase NAD+ preservation investigated for preservation of cellular NAD+ pools and downstream sirtuin pathway activity Adipose tissue research explored for lipolysis markers and fat-mass partitioning in DIO rodent models Skeletal muscle metabolism examined for endpoints related to muscle aging and sarcopenia models Metabolic signaling researched for glucose homeostasis and insulin sensitivity endpoints in metabolic disease models What Researchers Look At NNMT enzymatic activity and 1-methylnicotinamide (1-MNA) tissue concentrations Intracellular NAD+ / NADH ratio and downstream sirtuin (SIRT1/SIRT3) activation Body composition, fat mass, and lean mass partitioning in DIO rodent models Adipocyte lipolysis markers and adipose tissue inflammation profiles Glucose tolerance, insulin sensitivity, and hepatic steatosis endpoints Quick Specs Form: Lyophilized white powder Net Content: 50 mg per vial (as iodide salt) Quantity: 1 vial Appearance: White to off-white lyophilizate Reconstitution: Bacteriostatic or sterile water (added by the end researcher) Purity: 99% by HPLC Identity: MS-verified (per COA) Storage: Protect from light Identity Basics Compound: 5-Amino-1MQ (5-Amino-1-methylquinolinium iodide) Synonyms: 5-Amino-1-methylquinolinium
Structurally related to Melanotan-II but optimized for central, not peripheral, effects 1,2
Following the positive REDEFINE 1 Phase 3 data (published June 2025, PMID: 40544433), Novo Nordisk announced plans to file regulatory applications for CagriSema for obesity in the United States (FDA), European Union (EMA), and other major markets in 20252026
DOI: Published: Publisher Name: Humana, Cham Print ISBN: 978-3-031-13176-9 Online ISBN: 978-3-031-13177-6 eBook Packages: MedicineMedicine (R0)
